NEWRON PHARMACEUTICALS SPA (NP5.DE) Forecast, Price Target & Analyst Ratings

FRA:NP5 • IT0004147952

Current stock price

16.55 EUR
+0.5 (+3.12%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEWRON PHARMACEUTICALS SPA (NP5.DE).

Forecast Snapshot

Consensus Price Target

Price Target
€53.22
+ 221.59% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q2 / 2026
EPS Estimate
-€0.67
Revenue Estimate
6.732M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.22%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€53.22
Upside
+ 221.59%
From current price of €16.55 to mean target of €53.22, Based on 9 analyst forecasts
Low
€28.03
Median
€48.69
High
€85.10

Price Target Revisions

1 Month
0.00%
3 Months
164.90%

Price Target Summary

9 Wall Street analysts provided a forecast for the next 12 months for NP5.DE. The average price target is 53.22 EUR. This implies a price increase of 221.59% is expected in the next year compared to the current price of 16.55.
The average price target has been revised upward by 164.9% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

NP5 Current Analyst RatingNP5 Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

NP5 Historical Analyst RatingsNP5 Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
82.22%
NP5.DE was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about NP5.DE.
In the previous month the buy percentage consensus was at a similar level.
NP5.DE was analyzed by 9 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q2 / 2026
EPS Estimate
-€0.67
Revenue Estimate
6.732M
Revenue Q2Q
-43.42%
EPS Q2Q
-16,602.50%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
NP5.DE revenue by date.NP5.DE revenue by date.
6.094M
5.76%		9.057M
48.62%		51.39M
467.41%		17.309M
-66.32%		13.378M
-22.71%		41.222M
208.13%		8.977M
-78.22%		121.44M
1,252.79%		179.87M
48.11%		250.49M
39.26%		318.58M
27.18%		350.08M
9.89%
EBITDA
YoY % growth
NP5.DE ebitda by date.NP5.DE ebitda by date.
-13.1M
-7.84%		-11.428M
12.76%		26.365M
330.71%		-17.976M
-168.18%		-14.178M
21.13%		-8.42M
40.61%		152.36M
1,909.48%		135.15M
-11.30%		136.17M
0.75%		183.93M
35.07%		211.37M
14.92%		232.71M
10.10%
EBIT
YoY % growth
NP5.DE ebit by date.NP5.DE ebit by date.
-13.302M
-7.65%		-11.629M
12.58%		26.173M
325.07%		-9.721M
-137.14%		-27.221M
-180.02%		-23.868M
12.32%		152.36M
738.34%		135.15M
-11.30%		136.17M
0.75%		183.93M
35.07%		211.37M
14.92%		231.69M
9.61%
Operating Margin
NP5.DE operating margin by date.NP5.DE operating margin by date.
-218.28%-128.40%50.93%-56.16%-203.47%-57.90%1,697.23%111.29%75.70%73.43%66.35%66.18%
EPS
YoY % growth
NP5.DE eps by date.NP5.DE eps by date.
-0.98
-16.67%		-0.91
7.14%		0.85
193.41%		-0.86
-177.65%		-1.15
-74.33%		-0.40
64.98%		4.77
1,283.37%		4.21
-11.76%		4.64
10.39%		6.34
36.54%		7.18
13.30%		8.37
16.55%

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 26 Q4 / 26 Q2 / 27 Q4 / 27
EPS
Q2Q % growth		-0.67
-16,602.50%		-0.71
-8.84%		-0.55
18.32%		-0.75
-5.14%
Revenue
Q2Q % growth		6.732M
-43.42%		6.528M
-9.68%		N/AN/A
EBITDA
Q2Q % growth		1.459M
2.03%		-6.074M
46.64%		N/AN/A
EBIT
Q2Q % growth		-11.835M
-979.89%		-13.491M
-17.28%		N/AN/A

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

NP5.DE Yearly Revenue VS EstimatesNP5.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
NP5.DE Yearly EPS VS EstimatesNP5.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
109.72%
EPS Next 5 Year
55.31%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-19.66%
Revenue Next 5 Year
59.71%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-30.83%
EBIT Next 5 Year
30.92%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

NEWRON PHARMACEUTICALS SPA / NP5.DE Forecast FAQ

What do analysts expect the price target to be for NEWRON PHARMACEUTICALS SPA (NP5.DE)?

9 analysts have analysed NP5.DE and the average price target is 53.22 EUR. This implies a price increase of 221.59% is expected in the next year compared to the current price of 16.55.

What are the consensus estimates for NEWRON PHARMACEUTICALS SPA (NP5.DE) next earnings?

The consensus EPS estimate for the next earnings of NEWRON PHARMACEUTICALS SPA (NP5.DE) is -0.67 EUR and the consensus revenue estimate is 6.73M EUR.

What is the consensus rating for NP5 stock?

The consensus rating for NEWRON PHARMACEUTICALS SPA (NP5.DE) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.